Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Oct 20, 2023
Q3 2023 quarterly activity and cash flow report
Sep 14, 2023
Change of Director's Interest Notice - J Basile
Sep 01, 2023
S&P DJI Announces September 2023 Quarterly Rebalance
Aug 28, 2023
Investor presentation, 28 August 2023
Aug 28, 2023
Neuren reports 2023 half-year profit after tax of $48m
Aug 28, 2023
Half Yearly Report and Accounts
Aug 25, 2023
Notification of half-year results & investor web conference
Jul 31, 2023
Q2 2023 quarterly activity and cash flow report
Jul 27, 2023
Neuren receives US$100m for expanded DAYBUE agreement
Jul 14, 2023
Investor web conference presentation, 14 July 2023
Previous
1
2
3
4
5
Next
